Jun. 9 at 6:09 PM
$ACOG Jun 9, 2026 8:00 AM
https://www.businesswire.com/news/home/20260609909539/en/Alpha-Cognition-Reports-Positive-Top-Line-Results-from-BEACON-Real-World-Study-of-ZUNVEYL-in-Alzheimers-Disease
Interesting update from Alpha Cognition on the BEACON real-world study of ZUNVEYL in Alzheimer's disease.
The results appear encouraging, with physicians reporting improvements in cognition, neuropsychiatric symptoms, daily functioning and sleep in a large proportion of patients. The high level of physician satisfaction and the ability to delay or reduce certain psychotropic medications also stand out.
At the same time, it is important to keep the findings in perspective. This was a retrospective real-world study without a control group, so the data should not be viewed as a new clinical proof of efficacy or as a direct comparison with other Alzheimer's treatments.
These results still have value as they reflect experience from everyday clinical practice. Overall, a positive update—not a scientific breakthrough, but another building block supporting the practical use of ZUNVEYL in real-world settings.
